Silvio Inderbitzin
Chief Executive Officer at Mavena International AG
Net worth: 176 524 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rajwinder Lehal | M | 48 |
Cellestia Biotech AG
 Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | 10 years |
| Roger Meier | M | - |
Kinarus AG
 Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.
Aurealis Oy
 Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Marija Plodinec | M | - |
Artidis AG
 Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | - |
| Alexander Bausch | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Iain Peter Murray Buchanan | M | 72 |
Aurealis Pharma AG
 Aurealis Pharma AG Miscellaneous Commercial ServicesCommercial Services Part of Aurealis Oy, Aurealis Pharma AG is a Swiss company that provides scientific research and development services. The company is based in Basel, Switzerland. The company was founded by Juha Matti Yrjänheikki.
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Richard Ammer | M | 54 |
University of St. Gallen
| 23 years |
| Tobias Appenzeller | M | - |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | - |
| Philipp Oertle | M | - |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | - |
| Marko Loparic | M | - |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | - |
| Thomas Wirth | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | 14 years |
| Leanna Caron | F | 56 |
Nexilis AG
 Nexilis AG BiotechnologyHealth Technology Nexilis AG is a Swiss medtech company that specializes in providing cost-effective fixation enhancement for any bone screw. The private company's flagship product is the Immediate Stabilisation System (ISS), which is an implantable polymer sleeve that is moulded around the pedicle screw using ultrasonic energy. Nexilis has a culture built around innovative science, precision, and quality, and has engaged in collaborations with renowned institutions to create safe and easy-to-implement solutions for surgeons. The company was founded by Martin Horst and the CEO is Leanna Caron. | - |
| Richard Peck | M | 73 |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | 10 years |
| Juha Matti Yrjänheikki | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | 11 years |
| Martin Horst | M | - |
Nexilis AG
Nexilis AG BiotechnologyHealth Technology Nexilis AG is a Swiss medtech company that specializes in providing cost-effective fixation enhancement for any bone screw. The private company's flagship product is the Immediate Stabilisation System (ISS), which is an implantable polymer sleeve that is moulded around the pedicle screw using ultrasonic energy. Nexilis has a culture built around innovative science, precision, and quality, and has engaged in collaborations with renowned institutions to create safe and easy-to-implement solutions for surgeons. The company was founded by Martin Horst and the CEO is Leanna Caron. | - |
| Hari Kumar | M | 69 |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | 3 years |
| Rudolf Grünig | M | 70 |
Hänseler Holding AG
| - |
| Markus Forsberg | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Igor Mierau | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Laurent Marc Andre Décory | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
| Claudia Berger | F | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Eugene Tierney | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Eduard Enrico Holdener | M | 79 |
Swiss Cancer Foundation
| - |
| Matthew Wright | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Ajit Singh | M | 60 |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | 1 years |
| Reinhard Ambros | M | 67 |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | - |
| Trudi Haemmerli | F | - |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | - |
| Thierry Fumeaux | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | 3 years |
| Karen Chu | M | - |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | - |
| Friedrich Fahrni | M | 82 |
University of St. Gallen
| 24 years |
| Dominik Hauser | M | - |
Hänseler AG
 Hänseler AG Pharmaceuticals: MajorHealth Technology Hänseler AG manufactures and wholesales pharmaceutical products. It offers liquid, semi-solid and solid drug forms and drug substances in conformity with GMP. The firm manufactures galenical, which includes liquid, semi-solid and solid drug forms; and liquid extracts and tinctures. The company was founded by Edwin Hanseler in 1975 and is headquartered in Herisau, Switzerland. | - |
| Guido Guidi | M | 71 |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | - |
| Subhasis Roy | M | 55 |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Martin Gertsch | M | 59 |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | - |
| Hans Wehrli | M | 71 |
University of Zurich
| 31 years |
| Andreas Plückthun | M | 65 |
University of Zurich
| 31 years |
| David Epstein | M | 62 |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | 2 years |
| Thomas Rudolph | M | 62 |
University of St. Gallen
| 24 years |
| Robert Karsunky | M | - |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | - |
| Jean-Claude Clémençon | M | 62 |
Helvecura Cooperative Society
| - |
| Sandra Lienhart | F | 58 |
Swiss Cancer Foundation
| - |
| Christoph Meier | M | 70 |
Swiss Cancer Foundation
| - |
| Antti Poso | M | - |
Aurealis Oy
Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Anette Waygood | M | - |
University of St. Gallen
| 12 years |
| Rolf M. Zinkernagel | M | 80 |
University of Zurich
| 16 years |
| Philippe Weber | M | 59 |
University of Zurich
| 5 years |
| Rene Dittrich | M | 52 |
University of Zurich
| 6 years |
| Thomas Meier | M | - |
University of Zurich
| 6 years |
| Vanessa Frey | F | 44 |
University of St. Gallen
| 2 years |
| Michèle Florence Sutter-Rüdisser | M | 45 |
University of St. Gallen
| 5 years |
| Volker Kraft | M | 52 |
University of St. Gallen
| 7 years |
| Michael Sidler | M | 55 |
University of Zurich
| 8 years |
| Lukas Weder | M | - |
University of St. Gallen
| 5 years |
| Dominik Escher | M | - |
University of Zurich
| 8 years |
| Martin Weder | M | - |
University of St. Gallen
| 6 years |
| Benno Luechinger | M | - |
University of St. Gallen
| 6 years |
| Thomas Roland Meier | M | 61 |
University of Zurich
| 4 years |
| Joris Gröflin | M | 47 |
University of St. Gallen
| 1 years |
| Iris Bohnet Zürcher | M | 58 |
University of Zurich
| 5 years |
| Claude Stadler | M | 48 |
University of St. Gallen
| 2 years |
| Bruno Allemand | M | 59 |
University of St. Gallen
| 4 years |
| Mikhail Kart | M | 49 |
University of St. Gallen
| 2 years |
| Marc Meier | M | - |
University of St. Gallen
| 3 years |
| Werner Lüscher | M | - |
University of Zurich
| 2 years |
| Yvan Cardenas | M | 44 |
University of St. Gallen
| 1 years |
| Philipp Freyschlag | M | 43 |
University of St. Gallen
| 4 years |
| Silvan Zehnder | M | - |
University of St. Gallen
| 4 years |
| Wolf Witt | M | - |
University of St. Gallen
| 5 years |
| Ruedi Noser | M | 63 |
University of Zurich
| 4 years |
| Lars Nieba | M | 56 |
University of St. Gallen
| 2 years |
| Marcel Dillier | M | - |
University of Zurich
| 5 years |
| Ursula Nötzli | M | - |
University of St. Gallen
| 5 years |
| Horst Rzepka | M | 57 |
University of Zurich
| 2 years |
| Tobias Giesser | M | - |
University of St. Gallen
| 7 years |
| Alexander Ott | M | - |
University of St. Gallen
| 4 years |
| Adrian Eberle | M | 52 |
University of St. Gallen
| 3 years |
| Jan Schoch | M | 47 |
University of St. Gallen
| 4 years |
| Thomas Schönbucher | M | 51 |
University of St. Gallen
| 2 years |
| Urs Wälchli | M | 57 |
University of Zurich
| 1 years |
| Margret Suckale | F | 68 |
University of St. Gallen
| 3 years |
| Ulf Mainzer | M | 59 |
University of St. Gallen
| 1 years |
| Florian Schweitzer | M | - |
University of St. Gallen
| 4 years |
| Andreas Brinkrolf | M | - |
University of St. Gallen
| 2 years |
| Jochen Kriegmeier | M | 54 |
University of St. Gallen
| 3 years |
| Martin Schmid | M | 55 |
University of St. Gallen
| 3 years |
| Marcus Claessen | M | - |
University of St. Gallen
| 4 years |
| John von Berenberg-Consbruch | M | - |
University of St. Gallen
| 5 years |
| Nadine Blättler | F | 42 |
University of St. Gallen
| 4 years |
| Christoph Tonini | M | 54 |
University of St. Gallen
| 2 years |
| Andrea Sieber | F | 48 |
University of St. Gallen
| 3 years |
| Thomas Sieber | M | 61 |
University of St. Gallen
| 3 years |
| Markus Gygax | M | 62 |
University of St. Gallen
| 2 years |
| Catrina Luchsinger Gähwiler | M | - |
University of Zurich
| 3 years |
| Thomas Bischoff | M | 50 |
University of St. Gallen
| 1 years |
| Martin Steinmann | M | 68 |
University of St. Gallen
| 1 years |
| Ranjit de Sousa | M | - |
University of St. Gallen
| 3 years |
| Marcus Dimpfel | M | 50 |
University of St. Gallen
| 3 years |
| Thierry Léger | M | 58 |
University of St. Gallen
| 2 years |
| David Klein | M | 47 |
University of St. Gallen
| 4 years |
| Marc Mogalle | M | 50 |
University of St. Gallen
| 4 years |
| Michael Straka | M | - |
University of St. Gallen
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 94 | 94.00% |
| Finland | 8 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Silvio Inderbitzin
- Personal Network
